Browse Studies — Arctuva

Phase 2

A Phase 2 Non-comparative Screening Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy

This is a phase II, two-arm, noncomparative screening study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, admin…

Ovarian Clear Cell CarcinomaMetastatic Ovarian CancerRecurrent Ovarian Clear Cell Adenocarcinoma

Estimated

~$10 – $6,250

Tufts Medical CenterNCT07718854

Phase 3

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemothera…

Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more

Estimated

~$10 – $8,750

Genelux CorporationNCT05281471

Phase 1

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitum…

Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT04104776

Phase 1

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma

Ovarian Clear Cell Carcinoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06065462